Published in Lab Business Week, May 6th, 2007
The financing is accompanied by 10 million warrants at $0.75 and 10 million warrants at $2.00. The Company has agreed to register the shares involved in this financing.
Geert Kersten, Chief Executive Officer of CEL-SCI said, "These funds will allow us to move forward as planned to start our Phase III clinical trial in first line advanced primary head and neck cancer. This also...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week